Cannabis businesses face unique challenges and opportunities in this fast-paced, highly regulated industry. Since 2016, we have provided knowledgeable state regulatory and compliance support for client companies operating under state medical and adult-use regulations. Our commitment to understanding our clients’ products and business objectives allows us to deliver tailored solutions that foster success and growth.
With the DEA’s initiation of rulemaking proceedings to reschedule cannabis to Schedule III, the industry is poised for significant changes. This rescheduling is expected to ease legal constraints, facilitate access to banking services and traditional investments, and eliminate cumbersome tax burdens that prevent the deduction of ordinary business expenses. At Asebey Life Science Law, we are well-equipped to guide our clients through this transition, helping them capitalize on new opportunities and ensure compliance with evolving regulations.
As subject matter experts and authors of the legal treatise Legal Guide to the Business of Marijuana: Cannabis, Hemp, and CBD Regulation (PLI Press, 2024), our lead attorneys offer unparalleled insights into the intricate legal and regulatory landscape of the cannabis industry